secwatch / observer
8-K filed June 11, 2026, 4:15 PM ET ticker ZOMDF CIK 0001684144
other material confidence high sentiment negative materiality 0.15

Zomedica shareholders reject advisory vote on executive compensation at 2026 annual meeting

Zomedica Corp.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Zomedica Corp. shareholders approved Election of eight directors, each for a one-year term at the 2026-06-10 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-06-10
Exact text from the filing
Proposal 1: Election of Eight Directors For Withheld Broker Non-Vote Jeffrey Rowe 148,970,700 80,211,388 200,401,611 Robert Cohen 141,153,095 88,028,993 200,401,611 Chris Macleod 141,041,101 88,140,987 200,401,611 Pam Nichols 146,791,443 82,390,645 200,401,611 Johnny D. Powers 151,457,102 77,724,986 200,401,611 Sean Whelan 141,437,085 87,745,003 200,401,611 Rodney Williams 141,615,934 87,566,154 200,401,611 Larry Heaton 148,997,578 80,184,510 200,401,611
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Zomedica Corp. shareholders approved Ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm for 2026 at the 2026-06-10 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-10
Exact text from the filing
Proposal 2: Ratification of Independent Auditors For: 403,285,558 Withheld: 26,298,141
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Zomedica Corp. shareholders rejected Advisory vote to approve the compensation of our named executive officers as described in our management information circular and proxy statement for the Annual Meeting at the 2026-06-10 meeting.

Proposal
say on pay
Outcome
failed
Meeting
2026-06-10
Exact text from the filing
Proposal 3: Advisory Vote on the Company’s Executive Compensation The votes cast on the advisory vote to approve the compensation of our named executive officers disclosed in our management information circular and proxy statement for the Annual Meeting were as follows: For: 99,891,977 Against: 129,290,109 Broker Non-Vote 200,401,613
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Zomedica Corp. shareholders approved Amendment to the By-Laws of the Company to address the quorum requirements for an adjourned meeting of Shareholders at the 2026-06-10 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2026-06-10
Exact text from the filing
Proposal 4 ; Amendment of the Company’s By-Laws The votes cast to approve an amendment to the By-Laws of the Company to address the quorum requirements for an adjourned meeting of Shareholders as described in the our management information circular and proxy statement for the Annual Meeting were as follows: . For: 123,410,315 Against: 105,771,772 Broker Non-Vote 200,401,613
View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Zomedica Corp. filing history →

Source: SEC EDGAR
accession 0001654954-26-005904
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.